| Year |
Citation |
Score |
| 2022 |
Walters JN, Schouest B, Patel A, Reuschel EL, Schultheis K, Parzych E, Maricic I, Gary EN, Purwar M, Andrade VM, Doan A, Elwood D, Eblimit Z, Nguyen B, Frase D, et al. Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. Vaccine. 40: 2960-2969. PMID 35428500 DOI: 10.1016/j.vaccine.2022.03.060 |
0.404 |
|
| 2022 |
Xu Z, Walker S, Wise MC, Chokkalingam N, Purwar M, Moore A, Tello-Ruiz E, Wu Y, Majumdar S, Konrath KM, Kulkarni A, Tursi NJ, Zaidi FI, Reuschel EL, Patel I, et al. Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer. Nature Communications. 13: 695. PMID 35121758 DOI: 10.1038/s41467-022-28363-z |
0.357 |
|
| 2022 |
Konrath KM, Liaw K, Wu Y, Zhu X, Walker SN, Xu Z, Schultheis K, Chokkalingam N, Chawla H, Du J, Tursi NJ, Moore A, Adolf-Bryfogle J, Purwar M, Reuschel EL, et al. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection. Cell Reports. 110318. PMID 35090597 DOI: 10.1016/j.celrep.2022.110318 |
0.365 |
|
| 2022 |
Kraynyak KA, Blackwood E, Agnes J, Tebas P, Giffear M, Amante D, Reuschel EL, Purwar M, Christensen-Quick A, Liu N, Andrade VM, Diehl MC, Wani S, Lupicka M, Sylvester A, et al. SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial. The Journal of Infectious Diseases. PMID 35079784 DOI: 10.1093/infdis/jiac016 |
0.384 |
|
| 2021 |
Andrade VM, Christensen-Quick A, Agnes J, Tur J, Reed C, Kalia R, Marrero I, Elwood D, Schultheis K, Purwar M, Reuschel E, McMullan T, Pezzoli P, Kraynyak K, Sylvester A, et al. INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. Npj Vaccines. 6: 121. PMID 34650089 DOI: 10.1038/s41541-021-00384-7 |
0.437 |
|
| 2021 |
Patel A, Walters JN, Reuschel EL, Schultheis K, Parzych E, Gary EN, Maricic I, Purwar M, Eblimit Z, Walker SN, Guimet D, Bhojnagarwala P, Adeniji OS, Doan A, Xu Z, et al. Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model. Cell Reports. Medicine. 100420. PMID 34604818 DOI: 10.1016/j.xcrm.2021.100420 |
0.424 |
|
| 2021 |
Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, White S, Khan AS, Racine T, Choi H, Boyer J, Park YK, Trottier S, Remigio C, Krieger D, et al. Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine. The New England Journal of Medicine. 385: e35. PMID 34525286 DOI: 10.1056/NEJMoa1708120 |
0.317 |
|
| 2021 |
Patel A, Reuschel EL, Xu Z, Zaidi FI, Kim KY, Scott DP, Mendoza J, Ramos S, Stoltz R, Feldmann F, Okumura A, Meade-White K, Haddock E, Thomas T, Rosenke R, et al. Intradermal delivery of a synthetic DNA vaccine protects macaques from Middle East respiratory syndrome coronavirus. Jci Insight. PMID 33886507 DOI: 10.1172/jci.insight.146082 |
0.35 |
|
| 2020 |
Tebas P, Yang S, Boyer JD, Reuschel EL, Patel A, Christensen-Quick A, Andrade VM, Morrow MP, Kraynyak K, Agnes J, Purwar M, Sylvester A, Gillespie E, Maricic I, Zaidi FI, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. Eclinicalmedicine. 100689. PMID 33392485 DOI: 10.1016/j.eclinm.2020.100689 |
0.35 |
|
| 2020 |
Choi H, Kudchodkar SB, Ho M, Reuschel EL, Reynolds E, Xu Z, Bordoloi D, Ugen KE, Tebas P, Kim J, Abdel-Mohsen M, Thangamani S, Weiner DB, Muthumani K. A novel synthetic DNA vaccine elicits protective immune responses against Powassan virus. Plos Neglected Tropical Diseases. 14: e0008788. PMID 33119599 DOI: 10.1371/journal.pntd.0008788 |
0.399 |
|
| 2020 |
Walker SN, Chokkalingam N, Reuschel EL, Purwar M, Xu Z, Gary EN, Kim KY, Helble M, Schultheis K, Walters J, Ramos S, Muthumani K, Smith TRF, Broderick KE, Tebas P, et al. SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients. Journal of Clinical Microbiology. PMID 32855181 DOI: 10.1128/Jcm.01533-20 |
0.385 |
|
| 2020 |
Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J, Gary EN, Walker SN, Schultheis K, Purwar M, Xu Z, Walters J, Bhojnagarwala P, Yang M, Chokkalingam N, ... ... Reuschel EL, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nature Communications. 11: 2601. PMID 32433465 DOI: 10.1038/S41467-020-16505-0 |
0.492 |
|
| 2020 |
Reeder SM, Reuschel EL, Bah MA, Yun K, Tursi NJ, Kim KY, Chu J, Zaidi FI, Yilmaz I, Hart RJ, Perrin B, Xu Z, Humeau L, Weiner DB, Aly ASI. Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Challenge in a Mouse Model. Vaccines. 8. PMID 31936739 DOI: 10.3390/Vaccines8010021 |
0.511 |
|
| 2019 |
Choi H, Kudchodkar SB, Reuschel EL, Asija K, Borole P, Agarwal S, Van Gorder L, Reed CC, Gulendran G, Ramos S, Broderick KE, Kim JJ, Ugen KE, Kobinger G, Siegel DL, et al. Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge. Human Vaccines & Immunotherapeutics. 1-12. PMID 31799896 DOI: 10.1080/21645515.2019.1688038 |
0.482 |
|
| 2019 |
Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. The Lancet. Infectious Diseases. PMID 31351922 DOI: 10.1016/S1473-3099(19)30266-X |
0.421 |
|
| 2019 |
Choi H, Kudchodkar SB, Reuschel EL, Asija K, Borole P, Ho M, Wojtak K, Reed C, Ramos S, Bopp NE, Aguilar PV, Weaver SC, Kim JJ, Humeau L, Tebas P, et al. Protective immunity by an engineered DNA vaccine for Mayaro virus. Plos Neglected Tropical Diseases. 13: e0007042. PMID 30730897 DOI: 10.1371/Journal.Pntd.0007042 |
0.488 |
|
| 2019 |
Perales-Puchalt A, Svoronos N, Villarreal DO, Zankharia U, Reuschel E, Wojtak K, Payne KK, Duperret EK, Muthumani K, Conejo-Garcia JR, Weiner DB. IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment. Oncoimmunology. 8: e1515058. PMID 30546956 DOI: 10.1080/2162402X.2018.1515058 |
0.316 |
|
| 2018 |
Patel A, Reuschel EL, Kraynyak KA, Racine T, Park DH, Scott VL, Audet J, Amante D, Wise MC, Keaton AA, Wong G, Villarreal DO, Walters J, Muthumani K, Shedlock DJ, et al. Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines. The Journal of Infectious Diseases. PMID 30304515 DOI: 10.1093/Infdis/Jiy537 |
0.452 |
|
| 2018 |
Kudchodkar SB, Choi H, Reuschel EL, Esquivel R, Jin-Ah Kwon J, Jeong M, Maslow JN, Reed CC, White S, Kim JJ, Kobinger GP, Tebas P, Weiner DB, Muthumani K. Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus. Microbes and Infection. PMID 29555345 DOI: 10.1016/J.Micinf.2018.03.001 |
0.428 |
|
| 2017 |
Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, White S, Khan AS, Racine T, Choi H, Boyer J, Park YK, Trottier S, Remigio C, Krieger D, et al. Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. The New England Journal of Medicine. PMID 28976850 DOI: 10.1056/Nejmoa1708120 |
0.459 |
|
| 2017 |
Muthumani K, Marnin L, Kudchodkar SB, Perales-Puchalt A, Choi H, Agarwal S, Scott VL, Reuschel EL, Zaidi FI, Duperret EK, Wise MC, Kraynyak KA, Ugen KE, Sardesai NY, Joseph Kim J, et al. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. Cancer Immunology, Immunotherapy : Cii. PMID 28819703 DOI: 10.1007/S00262-017-2042-7 |
0.349 |
|
| 2017 |
Tebas P, Roberts CC, Muthumani K, Reuschel E, White S, Khan AS, Racine T, Choi H, Zaidi F, Boyer J, Kudchodkar S, Park YK, Trottier S, Remigio C, Krieger D, et al. ZIKA-001: Safety and Immunogenicity of an Engineered DNA Vaccine Against ZIKA virus infection Open Forum Infectious Diseases. 4: S300-S301. DOI: 10.1093/Ofid/Ofx163.693 |
0.405 |
|
| 2016 |
Muthumani K, Griffin BD, Agarwal S, Kudchodkar SB, Reuschel EL, Choi H, Kraynyak KA, Duperret EK, Keaton AA, Chung C, Kim YK, Booth SA, Racine T, Yan J, Morrow MP, et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. Npj Vaccines. 1: 16021. PMID 29263859 DOI: 10.1038/npjvaccines.2016.21 |
0.389 |
|
| 2016 |
Finkel TH, Li J, Wei Z, Wang W, Zhang H, Behrens EM, Reuschel EL, Limou S, Wise C, Punaro M, Becker ML, Munro JE, Flatø B, Førre Ø, Thompson SD, et al. Variants in CXCR4 associate with juvenile idiopathic arthritis susceptibility. Bmc Medical Genetics. 17: 24. PMID 27005825 DOI: 10.1186/S12881-016-0285-3 |
0.492 |
|
| 2016 |
Muthumani K, Block P, Flingai S, Muruganantham N, Chaaithanya IK, Tingey C, Wise M, Reuschel EL, Chung C, Muthumani A, Sarangan G, Srikanth P, Khan AS, Vijayachari P, Sardesai NY, et al. Rapid and long-term immunity elicited by DNA encoded antibody prophylaxis and DNA vaccination against Chikungunya virus. The Journal of Infectious Diseases. PMID 27001960 DOI: 10.1093/Infdis/Jiw111 |
0.469 |
|
| 2016 |
Ferraro B, Walters JN, Reuschel EL, Balakrishnan A, Morrow MP, Khan AS, Sardesai NY, Humeau LM, Weiner DB. Abstract LB-253: Control of tumor growth in vivo by a synthetic multi-antigen DNA immune therapy for prostate cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-253 |
0.467 |
|
| 2016 |
Patel A, Reuschel EL, Kraynyak KA, Racine T, Park DH, Keaton AA, Karuppiah M, Shedlock D, Yan J, Khan A, Tierney K, Sardesai N, Kobinger GP, Weiner DB. 479. An Optimized DNA Vaccine Formulation Protects Against Lethal Ebola Makona Virus Challenge in Non-Human Primates and Elicits Robust Immune Responses Molecular Therapy. 24: S189-S190. DOI: 10.1016/S1525-0016(16)33288-9 |
0.475 |
|
| 2016 |
Reuschel EL, Muthumani K, Kraynyak K, Tingey C, Kudchodkar SB, Khan AS, Sardesai NY, Kim JJ, Maslow J, Park YK, Kobinger G, Falzarano D, Feldman H, Weiner DB. 436. Developing a Synthetic DNA Vaccine for an Emerging Pathogen - Middle East Respiratory Syndrome Molecular Therapy. 24: S172-S173. DOI: 10.1016/S1525-0016(16)33245-2 |
0.519 |
|
| 2015 |
Reuschel EL, Wang J, Shivers DK, Muthumani K, Weiner DB, Ma Z, Finkel TH. REDD1 Is Essential for Optimal T Cell Proliferation and Survival. Plos One. 10: e0136323. PMID 26301899 DOI: 10.1371/Journal.Pone.0136323 |
0.572 |
|
| 2015 |
Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaid A, Seliga AM, Soule G, Morrow M, Kraynyak KA, Khan AS, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Science Translational Medicine. 7: 301ra132. PMID 26290414 DOI: 10.1016/J.Ijid.2016.02.083 |
0.481 |
|
| 2015 |
Patel A, Reuschel EL, Scott VL, Kraynyak KA, Wong G, Villarreal DO, Karuppiah M, Shedlock D, Yan J, Broderick KE, Khan A, Tierney K, Kobinger GP, Sardesai N, Weiner DB. 450. A Single Immunization With Optimized DNA Vaccines Protects Against Lethal Ebola Virus Challenge in Mice and Induces Seroconversion in Non-Human Primates Following a DNA Prime–DNA Boost Approach Molecular Therapy. 23: S178-S179. DOI: 10.1016/S1525-0016(16)34059-X |
0.5 |
|
| 2015 |
Ferraro B, Walters JN, Reuschel EL, Balakrishnan A, Morrow MP, Yan J, Khan AS, Sardesai NY, Humeau LM, Weiner DB. 210. Complete Control of Tumor Growth In Vivo By a Synthetic Consensus Multi-Antigen DNA Immune Therapy for Prostate Cancer Molecular Therapy. 23: S83. DOI: 10.1016/S1525-0016(16)33815-1 |
0.478 |
|
| 2014 |
Shedlock DJ, Tingey C, Mahadevan L, Hutnick N, Reuschel EL, Kudchodkar S, Flingai S, Yan J, Kim JJ, Ugen KE, Weiner DB, Muthumani K. Co-Administration of Molecular Adjuvants Expressing NF-Kappa B Subunit p65/RelA or Type-1 Transactivator T-bet Enhance Antigen Specific DNA Vaccine-Induced Immunity. Vaccines. 2: 196-215. PMID 26344618 DOI: 10.3390/Vaccines2020196 |
0.506 |
|
| 2014 |
Yan J, Tingey C, Lyde R, Gorham TC, Choo DK, Muthumani A, Myles D, Weiner LP, Kraynyak KA, Reuschel EL, Finkel TH, Kim JJ, Sardesai NY, Ugen KE, Muthumani K, et al. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model. Cancer Gene Therapy. 21: 507-17. PMID 25394503 DOI: 10.1038/Cgt.2014.56 |
0.615 |
|
| 2014 |
Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP, Weiner DB. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Research. 74: 1789-800. PMID 24448242 DOI: 10.1158/0008-5472.Can-13-2729 |
0.454 |
|
| 2011 |
Wang J, Reuschel EL, Shackelford JM, Jeang L, Shivers DK, Diehl JA, Yu XF, Finkel TH. HIV-1 Vif promotes the G₁- to S-phase cell-cycle transition. Blood. 117: 1260-9. PMID 21149631 DOI: 10.1182/blood-2010-06-289215 |
0.507 |
|
| Show low-probability matches. |